OBJECTIVE: To test whether a reduction of third generation cephalosporin (3GC) use has a sustainable positive impact on the high endemic prevalence of 3GC resistant K. pneumoniae and E. coli. DESIGN: Segmented regression analysis of interrupted time series was used to analyse antibiotic consumption and resistance data 30 months before and 30 after the intervention. SETTING: Surgical intensive care unit (ICU) with 16-bed unit in a teaching hospital. INTERVENTION: In July 2004, 3GCs were switched to piperacillin in combination with a beta-lactamase-inhibitor as standard therapy for peritonitis and other intraabdominal infections. RESULTS: Segmented regression analysis showed that the intervention achieved a significant and sustainable decrease in the use of 3GCs of -110.2 daily defined doses (DDD)/1,000 pd. 3GC use decreased from a level of 178.9 DDD/1,000 pd before to 68.7 DDD/1,000 pd after the intervention. The intervention resulted in a mean estimated reduction in total antibiotic use of 27%. Piperacillin/tazobactam showed a significant increase in level of 64.4 DDD/1,000 pd, and continued to increase by 2.3 DDD/1,000 pd per month after the intervention. The intervention was not associated with a significant change in the resistance densities of 3GC resistant K. pneumoniae and E. coli. CONCLUSION: Reducing 3GCs does not necessarily impact positively on the resistance situation in the ICU setting. Likewise, replacing piperacillin with beta-lactamase inhibitor might provide a selection pressure on 3GC resistant E. coli and K. pneumoniae. To improve resistance, it might not be sufficient to restrict interventions to a risk area.
OBJECTIVE: To test whether a reduction of third generation cephalosporin (3GC) use has a sustainable positive impact on the high endemic prevalence of 3GC resistant K. pneumoniae and E. coli. DESIGN: Segmented regression analysis of interrupted time series was used to analyse antibiotic consumption and resistance data 30 months before and 30 after the intervention. SETTING: Surgical intensive care unit (ICU) with 16-bed unit in a teaching hospital. INTERVENTION: In July 2004, 3GCs were switched to piperacillin in combination with a beta-lactamase-inhibitor as standard therapy for peritonitis and other intraabdominal infections. RESULTS: Segmented regression analysis showed that the intervention achieved a significant and sustainable decrease in the use of 3GCs of -110.2 daily defined doses (DDD)/1,000 pd. 3GC use decreased from a level of 178.9 DDD/1,000 pd before to 68.7 DDD/1,000 pd after the intervention. The intervention resulted in a mean estimated reduction in total antibiotic use of 27%. Piperacillin/tazobactam showed a significant increase in level of 64.4 DDD/1,000 pd, and continued to increase by 2.3 DDD/1,000 pd per month after the intervention. The intervention was not associated with a significant change in the resistance densities of 3GC resistant K. pneumoniae and E. coli. CONCLUSION: Reducing 3GCs does not necessarily impact positively on the resistance situation in the ICU setting. Likewise, replacing piperacillin with beta-lactamase inhibitor might provide a selection pressure on 3GC resistant E. coli and K. pneumoniae. To improve resistance, it might not be sufficient to restrict interventions to a risk area.
Authors: Johann D D Pitout; Daniel B Gregson; Deirdre L Church; Sameer Elsayed; Kevin B Laupland Journal: J Clin Microbiol Date: 2005-06 Impact factor: 5.948
Authors: Anthony D Harris; Jessina C McGregor; Judith A Johnson; Sandra M Strauss; Anita C Moore; Harold C Standiford; Joan N Hebden; J Glenn Morris Journal: Emerg Infect Dis Date: 2007-08 Impact factor: 6.883
Authors: Peter Davey; Charis A Marwick; Claire L Scott; Esmita Charani; Kirsty McNeil; Erwin Brown; Ian M Gould; Craig R Ramsay; Susan Michie Journal: Cochrane Database Syst Rev Date: 2017-02-09
Authors: Tiscar Graells; Irene A Lambraki; Melanie Cousins; Anaïs Léger; Kate Lillepold; Patrik J G Henriksson; Max Troell; Carolee A Carson; Elizabeth Jane Parmley; Shannon E Majowicz; Didier Wernli; Peter Søgaard Jørgensen Journal: Antibiotics (Basel) Date: 2022-05-10
Authors: Massimo Antonelli; Elie Azoulay; Marc Bonten; Jean Chastre; Giuseppe Citerio; Giorgio Conti; Daniel De Backer; François Lemaire; Herwig Gerlach; Goran Hedenstierna; Michael Joannidis; Duncan Macrae; Jordi Mancebo; Salvatore M Maggiore; Alexandre Mebazaa; Jean-Charles Preiser; Jerôme Pugin; Jan Wernerman; Haibo Zhang Journal: Intensive Care Med Date: 2010-01-08 Impact factor: 17.440
Authors: Priscila R Oliveira; Adriana P Paula; Karine Dal-Paz; Cassia S Felix; Flavia Rossi; Jorge S Silva; Ana Lucia M Lima Journal: Infect Drug Resist Date: 2011-08-04 Impact factor: 4.003
Authors: Miroslava Htoutou Sedláková; Karel Urbánek; Vladimíra Vojtová; Hana Suchánková; Peter Imwensi; Milan Kolář Journal: BMC Res Notes Date: 2014-07-16